If you want to make a complex molecule for a drug or a semiconductor, you start with a recipe. These synthesis routes are often decades old, patched together over time, and notoriously wasteful. They are the legacy code of industrial chemistry. NuSynth Technologies, a Bengaluru startup founded last year, is proposing a ground-up rewrite.
Backed by a $4.4 million seed round, the company is building an AI-powered platform that aims to redesign chemical processes from first principles. The goal is not to tweak an existing reaction, but to find a fundamentally simpler, cheaper, and more efficient path to the same molecule [ET Pharma, October 2026]. It is a bet that the most expensive part of making a chemical is not the raw materials, but the intellectual debt in the process itself.
The Wedge: Process Over Product
NuSynth is not selling chemicals. It is selling the recipe. The company's commercial wedge is to develop proprietary manufacturing processes for high-value molecules in pharmaceuticals and electronic chemicals, then license them or partner with manufacturers to produce them [Indian Startup News, October 2026]. Its platform ingests experimental data to build a proprietary knowledge base, which it uses to simulate and evaluate new synthesis routes based on cost, yield, safety, and scalability [ET Pharma, October 2026].
This asset-light model is key. Rather than building its own factories, NuSynth has lined up a network of more than 20 manufacturing partners across India to handle scale-up and production [Indian Startup News, October 2026]. The company's value is in the intellectual property of the process design, a digital product with potentially high margins if it works.
The Team Built for the Grind
The founding team is structured to bridge the gap between deep science and industrial scale. CEO Poorvank Purohit is the former managing director and CEO of Solara Active Pharma Sciences, bringing decades of experience in commercializing active pharmaceutical ingredients [Bloomberg Markets, 2026]. His co-founder, Dr. Ramesha A. R., is a former postdoctoral researcher at the U.S. National Institutes of Health and a PhD from the Indian Institute of Science, providing the scientific heft [PERPLEXITY SONAR PRO BRIEF].
They are joined by Abhishek Deo and Dipak Bajaj, who bring operating and commercial experience from a mix of Indian startups and corporates like Zetwerk and Ola [PERPLEXITY SONAR PRO BRIEF]. It is a group assembled for the long, hard work of process innovation, where a brilliant reaction in a flask is meaningless if it cannot be reproduced at ton scale.
| Founder | Role | Key Background |
|---|---|---|
| Poorvank Purohit | Co-founder & CEO | Former MD/CEO, Solara Active Pharma Sciences [Bloomberg Markets, 2026] |
| Dr. Ramesha A. R. | Co-founder | Former NIH postdoc; PhD, Indian Institute of Science [PERPLEXITY SONAR PRO BRIEF] |
| Abhishek Deo | Co-founder | Commercial/operations roles at Zetwerk, Ola, others [PERPLEXITY SONAR PRO BRIEF] |
| Dipak Bajaj | Co-founder | Experience at Zetwerk, Ola, others [PERPLEXITY SONAR PRO BRIEF] |
The Capital and the Clock
The ₹36.5 crore (roughly $4.4 million) seed round, co-led by Avaana Capital and Shastra VC in October 2026, is fuel for the R&D engine [The Economic Times, October 2026]. The capital is earmarked for building the technology platform, developing an initial portfolio of proprietary processes, and expanding the team. The timeline is ambitious: the company expects to commercialize its first processes in the second half of 2027, following customer sampling and validation batches [Indian Startup News, October 2026].
This puts the company in a race against its own burn rate. Process development and validation is not software deployment; it involves physical experiments, regulatory considerations for pharma, and rigorous customer qualification. The seed round needs to fund the company through to its first commercial proofs, a period where patience is as important as capital.
The Credibility Test
The risks here are not subtle. They are the fundamental challenges of entering one of the world's most conservative and risk-averse industries. The company's success hinges on three core assumptions that will be tested in the next 18 months.
- Scientific novelty. The platform must consistently discover synthesis routes that are meaningfully better,in cost, yield, or sustainability,than the accumulated wisdom of global chemical R&D teams. Incremental gains will not justify the switching cost for manufacturers.
- Industrial validation. A process that works in a lab at gram scale must be proven in a partner's plant at kilogram or ton scale. This scale-up is where most novel chemistry fails, and NuSynth's network of 20 partners will be worthless if the processes cannot be reliably transferred.
- Commercial adoption. Even with a superior process, convincing chemical manufacturers to abandon a known, qualified route for an unproven one from a startup is a monumental sales challenge. The value proposition must be overwhelmingly clear.
The company's answer to these risks is its founding team's combined experience. Purohit knows how to sell to pharma companies; Ramesha knows what makes a reaction robust; Deo and Bajaj know how to manage complex operations. It is a team built to navigate exactly these hurdles.
The Unit Economics of a Reaction
The financial bet is easier to sketch out than the chemical one. Assume a target molecule used in a generic drug has a market of 100 tons per year, produced at a cost of $1,000 per kilogram. If NuSynth's process cuts the production cost by 15%,a significant but plausible improvement for a redesigned route,that saves $150 per kilogram, or $15 million annually across the market.
If NuSynth captures even a fraction of that value through licensing, the economics can scale quickly without the capital intensity of manufacturing. The company is not trying to beat a chemical giant at producing bulk commodities. It is trying to beat them at thinking. Its incumbent to outmaneuver is not a specific company, but the entire tradition of iterative process development inside large corporate R&D labs. That tradition is slow, expensive, and often trapped by its own history. NuSynth is betting that starting from a blank slate, with an AI co-pilot and a fresh team, is now a cheaper and faster way to find the best path.
Sources
- [The Economic Times, October 2026] NuSynth Technologies raises Rs 36.5 crore in round led by Avaana Capital, Shastra VC | https://economictimes.indiatimes.com/tech/funding/nusynth-technologies-raises-rs-36-5-crore-in-round-led-by-avaana-capital-shastra-vc/articleshow/134907930.cms
- [ET Pharma, October 2026] NuSynth Tech raises ₹36 cr in seed round to build AI-driven chemical synthesis platform | https://pharma.economictimes.indiatimes.com/news/start-ups/nusynth-tech-raises-36-cr-in-seed-round-to-build-ai-driven-chemical-synthesis-platform/134916133
- [Indian Startup News, October 2026] AI-powered chemical R&D startup NuSynth Technologies raises Rs 36.5 crore led by Avaana, Shastra VC | https://indianstartupnews.com/funding/ai-powered-chemical-rd-startup-nusynth-technologies-raises-rs-365-crore-led-by-avaana-shastra-vc-12671434
- [Bloomberg Markets, 2026] Poorvank Purohit, Solara Active Pharma Sciences Ltd: Profile and Biography | https://www.bloomberg.com/profile/person/23307509
- [PERPLEXITY SONAR PRO BRIEF] Web-grounded research summary on NuSynth Technologies, founders, and product